Intellia TherapeuticsNTLA

We expect revenue to grow from $0.1B in FY2026 to $3.5B in FY2031 (~126% CAGR), with EPS growing from $-3.22 to $11.50. Revenue scales rapidly as lead gene-editing therapies for ATTR and HAE transition from clinical trials to global commercial sales. Profit margins expand significantly as the high costs of drug development are spread across a growing base of recurring patient treatments. EPS grows faster than revenue because the company moves past its heavy R&D investment phase into a highly profitable commercial stage. Operating margin expected to reach ~40% by FY2031.

Regulatory approval of NTLA-2002 for HAE creates a commercial powerhouse. If approved, Intellia gains a first-in-class curative treatment in a multi-billion dollar market.

Expansion into other liver-directed diseases multiplies the addressable market. Success in ATTR proves the platform works, allowing Intellia to quickly launch trials for hemophilia and other liver disorders.

Partnership milestones provide non-dilutive funding for the pipeline. Reaching clinical goals triggers payments from Regeneron that extend the cash runway without selling more stock.

Phase 3 clinical data fails to meet efficacy or safety bars. A failure in the ATTR or HAE trials would destroy the thesis and most of the company's valuation.

New editing technologies like base or prime editing render CRISPR-Cas9 obsolete. If competitors develop safer or more efficient editing methods, Intellia's current pipeline could lose its market value.

Regulatory hurdles or safety concerns delay product launches. Even with good data, the FDA could demand longer safety monitoring, forcing the company to raise cash at a disadvantage.

Detailed deep dive on earnings update reports will be available soon for Pro members.

We use a 5-year Discounted Cash Flow (DCF) with a dual terminal value to determine the fair value. This fits Intellia because the company is currently losing money while building a high-value intellectual property pipeline; a DCF captures the long-term cash generation of these gene-editing "cures" better than any current revenue multiple.

The $198 fair value is based on the present value of projected cash flows through 2031 and a 30x terminal multiple applied to FY2031 earnings. A 30x multiple sits at the top end of the mature biotech range (Vertex 26x, Regeneron 22x, Amgen 18x) — a premium we believe is justified by the curative nature of CRISPR (gene-editing) therapies which command higher long-term pricing power. Our calculation uses the engine's ground-truth FY2031 EPS of $11.50 as the basis for the terminal value.

Cross-checked with a Forward P/E approach using FY2030 earnings, we arrive at a fair value of $205 — within 4% of our DCF answer of $198, confirming the result. Applying a 25x multiple to the projected FY2030 EPS of $8.20 shows that the valuation remains robust even when looking at mid-term profitability rather than a terminal exit. The two frameworks are in strong agreement, suggesting the $198 target is a reliable baseline for the company's commercial potential.

We're assuming Intellia achieves its first commercial launch for lead programs by late 2027. This timeline is supported by the current Phase 3 status of NTLA-2001 and management’s shift toward commercial manufacturing readiness, which suggests the platform is moving past the high-risk discovery phase.

We're assuming a 10% discount rate, also known as WACC (Weighted Average Cost of Capital). While the company's five-year beta (a measure of volatility) of 1.62 suggests a higher theoretical cost of equity, a 10% rate is the industry standard for valuing late-stage clinical pipelines with validated platforms and large addressable markets.

We're assuming the business reaches GAAP profitability by FY2029. Current projections show an inflection to $3.80 EPS (earnings per share) as high-margin therapeutic sales finally offset historical research and development spending, creating a clear path to self-funded growth.

The single biggest risk is a significant safety signal or adverse event in the Phase 3 trials for Intellia's lead gene-editing candidates. Such an event would likely halt the entire pipeline, compressing the fair value toward the company's net cash position of roughly $1.15 per share. Watch for any reports of "off-target" editing effects in the upcoming 2026 clinical data readouts.